SequelSEC

IRIDEX CORP IRIX

Electromedical & Electrotherapeutic Apparatus · CIK 0001006045 · Fiscal year ends 0103

AnnualQuarterlyTTM
Revenue
$12.57M
Fiscal year ended 2026-07-04
Operating income
-$1.03M
Fiscal year ended 2026-07-04
Free cash flow
$124.00K
Fiscal year ended 2026-07-04

IRIDEX CORP (IRIX) reported revenue of $12.57M and net income of -$1.27M for the fiscal year ended 2026-07-04. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from IRIDEX CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

IRIDEX CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-042026-04-042026-01-032025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Revenue$12.57M$11.80M$14.72M$12.48M$13.57M$11.90M$12.70M$11.58M$12.63M$11.76M
Cost of revenue$8.27M$7.06M$9.25M$8.47M$8.89M$6.84M$7.11M$7.26M$7.50M$7.30M
Gross profit$4.30M$4.74M$5.48M$4.01M$4.68M$5.06M$5.59M$4.32M$5.14M$4.46M
Operating income-$1.03M-$324.00K-$15.00K-$1.41M-$940.00K-$205.00K-$502.00K-$1.87M-$2.64M-$3.29M
Net income-$1.27M-$524.00K-$184.00K-$1.57M-$994.00K-$1.69M-$834.00K-$1.93M-$2.68M-$3.46M
Research & development$936.00K$905.00K$949.00K$972.00K$871.00K$876.00K$1.11M$1.30M$1.50M$1.54M
Weighted-average diluted sharesshares 17.42Mshares 17.31MUnavailableshares 17.01Mshares 16.79Mshares 16.73MUnavailableshares 16.58Mshares 16.29Mshares 16.25M
Pretax income-$1.20M-$466.00K-$164.00K-$1.57M-$973.00K-$1.67M-$840.00K-$1.92M-$2.66M-$3.43M
Income tax expense$70.00K$58.00K$20.00K$4.00K$21.00K$12.00K-$6.00K$17.00K$19.00K$38.00K
Diluted EPS$-0.07$-0.03$-0.01$-0.09$-0.06$-0.10$-0.05$-0.12$-0.16$-0.21
Selling, general & administrative$4.39M$4.16M$4.54M$4.45M$4.75M$4.38M$4.98M$4.89M$6.27M$6.22M
General & administrative$1.84M$1.62M$1.79M$1.80M$2.22M$1.93M$2.28M$2.25M$2.78M$2.47M
Selling & marketing$2.55M$2.54M$2.75M$2.66M$2.54M$2.45M$2.70M$2.65M$3.49M$3.75M

Balance

IRIDEX CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-042026-04-042026-01-032025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Cash & equivalents$4.68M$4.60M$6.03M$5.57M$6.78M$7.24M$2.39M$3.86M$4.11M$5.42M
Total assets$27.26M$28.27M$29.15M$28.35M$31.58M$34.24M$29.14M$30.15M$31.25M$34.09M
Current assets$23.96M$24.58M$25.25M$24.07M$26.87M$29.13M$23.56M$24.34M$25.01M$27.58M
Total liabilities$23.62M$23.54M$24.23M$23.67M$25.53M$27.38M$27.04M$27.53M$27.00M$27.60M
Current liabilities$13.17M$12.83M$13.21M$12.39M$13.71M$14.95M$16.56M$15.85M$16.14M$16.07M
Total equity incl. NCI$3.64M$4.73M$4.92M$4.68M$6.06M$852.00K$2.10M$2.62M$4.25M$6.49M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$9.75M$9.32M$7.88M$7.30M$8.44M$10.14M$10.82M$10.94M$11.12M$11.00M
Accounts receivable$5.67M$6.84M$7.61M$7.13M$7.14M$6.68M$5.95M$5.95M$6.27M$6.52M
Goodwill$965.00K$965.00K$965.00K$965.00K$965.00K$965.00K$965.00K$965.00K$965.00K$965.00K
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$1.00M$1.40MUnavailableUnavailable
Accounts payable$6.65M$5.75M$5.38M$4.41M$5.31M$6.05M$6.98M$6.20M$7.77M$7.68M

Cash flow

IRIDEX CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-042026-04-042026-01-032025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Operating cash flow$174.00K-$1.34M$589.00K-$1.16M-$397.00K-$1.15M-$1.24M-$3.07M-$1.33M-$1.65M
Capital expenditures$50.00K$101.00K$106.00K$13.00K$13.00K$11.00K$9.00K$1.00K$0$3.00K
Investing cash flow-$50.00K-$101.00K-$106.00K-$13.00K-$13.00K-$11.00K-$9.00K-$1.00K$0-$3.00K
Financing cash flow-$38.00K-$1.00K-$27.00K-$34.00K-$14.00K$6.04M-$218.00K$2.82M$0$0
Net change in cash$85.00K-$1.43M$455.00K-$1.20M-$466.00K$4.86M-$1.47M-$251.00K-$1.31M-$1.62M
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$86.00K$100.00K$151.00K$110.00K$127.00K$135.00K$135.00K$137.00K$139.00K$173.00K

Derived

IRIDEX CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-042026-04-042026-01-032025-09-272025-06-282025-03-292024-12-282024-09-282024-06-292024-03-30
Free cash flow$124.00K-$1.44M$483.00K-$1.17M-$410.00K-$1.16M-$1.25M-$3.07M-$1.33M-$1.65M
Gross margin34.2%40.2%37.2%32.1%34.5%42.5%44.0%37.3%40.7%37.9%
Operating margin-8.2%-2.7%-0.1%-11.3%-6.9%-1.7%-4.0%-16.1%-20.9%-28.0%
FCF margin1.0%-12.2%3.3%-9.4%-3.0%-9.8%-9.8%-26.5%-10.5%-14.0%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.82x1.92x1.91x1.94x1.96x1.95x1.42x1.54x1.55x1.72x
Revenue YoY growth-7.4%-0.8%16.0%7.8%7.4%1.1%1.9%-9.9%-1.7%-14.2%
Net margin-10.1%-4.4%-1.2%-12.6%-7.3%-14.2%-6.6%-16.7%-21.2%-29.5%
R&D / revenue7.4%7.7%6.4%7.8%6.4%7.4%8.8%11.2%11.9%13.1%
CapEx / revenue0.4%0.9%0.7%0.1%0.1%0.1%0.1%0.0%0.0%0.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IRIX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-18View SEC filing
10-Q · Filed 2026-05-19View SEC filing
10-K · Filed 2026-04-02View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2025-03-29

Difference 6000000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.